A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

What this study is about

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

Who can join (things the study team will check)

✅ You may be able to join if…

• Males \& females (inclusive of all gender identities) age ≥18 years
• BMI ≥27 kg/m2
• Diagnosed with T2DM ≥90 days prior to Screening
• HbA1c value at Screening of ≥6.0% (42 mmol/mol) and ≤10% (86 mmol/mol) managed with diet and exercise alone or with a stable dose of any oral glycaemic-lowering agent (as per local labelling)
• Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation
• History of at least one self-reported unsuccessful attempt to lose body weight in lifetime

🚫 You may not be able to join if…

• Obesity primarily caused by other endocrine disorders
• Type 1 diabetes mellitus (or any other diabetes mellitus that is not clearly Type 2 diabetes), OR have history of ketoacidosis or hyperosmolar coma/state within 3 months prior to Screening
• Significant hepatobiliary disease and/or any of the following results at Screening:
  • ALT ≥ 3.0 X ULN
  • AST ≥ 3.0 X ULN
  • TBL > 1.5 X ULN (except for cases of known Gilbert's Syndrome)
• Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation
• Use of insulin therapy for T2DM within 3 months prior to screening

Where this trial is running

• Research Site, Fairhope, Alabama, United States
• Research Site, Huntsville, Alabama, United States
• Research Site, Mesa, Arizona, United States
• Research Site, Phoenix, Arizona, United States
• Research Site, Tucson, Arizona, United States
• Research Site, Little Rock, Arkansas, United States
• Research Site, Bakersfield, California, United States
• Research Site, Gardena, California, United States
• Research Site, Lincoln, California, United States
• Research Site, Torrance, California, United States
• Research Site, Walnut Creek, California, United States
• Research Site, Coral Gables, Florida, United States

+ 206 more sites.

Who to contact

AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07784270.